The AudioNotch Tinnitus Treatment Blog

One of the issues plaguing scientific research is the tendency to avoid publishing negative study results – i.e. if something DIDN’T work, people are far less prone to publish a scientific paper about it. That’s why it’s heartening to see research like this, on why L-baclofen doesn’t appear to work in animal models of tinnitus:

Subjective tinnitus is a chronic neurological disorder in which phantom sounds are perceived. Recent evidence supports the hypothesis that tinnitus is related to neuronal hyperactivity in auditory brain regions, and consequently drugs that increase GABAergic neurotransmission in the CNS, such as the GABAB receptor agonist L-baclofen, may be effective as a treatment. The aim of this study was to investigate the effects of early (5 mg/kg s.c., 30 min and then every 24 h for 5 days following noise exposure) and late treatment (3 mg/kg/day s.c. for 4.5 weeks starting at 17.5 weeks following noise exposure) with L-baclofen on the psychophysical attributes of tinnitus in a conditioned lick suppression model following acoustic trauma in rats. Acoustic trauma (a 16 kHz, 115 dB pure tone presented unilaterally for 1 h) resulted in a significant decrease in the suppression ratio (SR) compared to sham controls in response to 20 kHz tones at 2, 10 and 17.5 weeks post-exposure (P ⩽ 0.009, P ⩽ 0.02 and P ⩽ 0.03, respectively). However, L-baclofen failed to prevent the development of tinnitus when administered during the first 5 days following the acoustic trauma and also failed to reverse it when treatment was carried out every day for 4.5 weeks. We also found that treatment with L-baclofen did not alter the expression of the GABAB-R2 subunit in the cochlear nucleus of noise-exposed animals.